Back to top

Vanda Pharmaceuticals (VNDA) Jumps: Stock Gains 12.1%

Read MoreHide Full Article

Vanda Pharmaceuticals, Inc. (VNDA - Free Report) was a big mover last session with its shares rising just over 12% on the day. The upside was owing to the announcement that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation at the Jefferies Global Healthcare Conference in New York City on June 4, 2015. This development led to far more shares changing hands yesterday than in a normal session. The move continues the recent uptrend of the company as the stock has gained over 20% in the past one-month time frame.

This biopharmaceutical company that develops products for the treatment of central nervous system disorders has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this stock in the near future.

Vanda currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the biomedical industry may consider Actelion Ltd. which sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Vanda Pharmaceuticals Inc. (VNDA) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in